Merck pays $250m to develop and commercialize personalized cancer vaccine with Moderna 13-Oct-2022 By Rachel Arthur Merck has exercised its option to jointly develop and commercialize a personalized cancer vaccine (PVC) with Moderna following 'significant progress' made by the two companies in the field to date.